CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Eli Lilly
Main (gene editing) focus: Genetic disorders in the liver and nervous system
Company stage: Commercial
Diseases (gene editing): Liver diseases and diseases of the central nervous system
Genome editing tool: ADAR RNA editing, Arcus Meganuclease
Funding stage: Public (NASDAQ:LLY)
Location: Indianapolis, Indiana, USA
Website: https://www.lilly.com/
Pipeline: https://www.lilly.com/discovery/clinical-development-pipeline
Gene editing partnerships: ProQR Therapeutics, Precision Biosciences
Eli Lilly is a big pharma company with several commercialised medicines in its portfolio. The company's involvment in the genome-editing space comes primarily through its collaboration with Precision Biosciences, where Eli Lilly gets access to the ARCUS meganuclease gene-editing technology to treat genetic diseases of muscle, CNS and liver. Another collaboration in this space is with ProQR Therapeutics, where Eli Lilly gains access to an ADAR-based RNA-editing technology.
